Pfizer said Wednesday it has signed a $1.95 billion pact to provide the U.S. government with 100 million doses of a COVID-19 vaccine. Americans will receive the vaccine for free, the pharmaceutical company said.
The deal for the vaccine, which is being developed with BioNTech, includes the right to purchase up to an additional 500 million doses, Pfizer said in a statement. Pfizer said it's on track to start the next safety and efficacy trial later this month, and is aiming to seek regulatory review as early as October. It could manufacture up to 100 million doses by the end of 2020, it added.
Source: Pfizer in pact to provide U.S. with 100 million COVID-19 vaccine doses
The New York Times has a Coronavirus Vaccine Tracker which it updates regularly. Here is a link:
Coronavirus Vaccine Tracker Researchers are currently working on approximately 165 vaccines worldwide. This resource provides current status on these vaccines.
The site lists the following status on the Pfizer vaccine:
The German company BioNTech has entered into collaborations with Pfizer, based in New York, and the Chinese drug maker Fosun Pharma to develop their mRNA vaccine. In July, they posted preliminary results from their Phase I/II trials in the United States and Germany. They found that the volunteers produced antibodies against SARS-CoV-2, as well as immune cells called T cells that respond to the virus. Some volunteers experienced moderate side effects such as sleep disturbances and sore arms.
The company expects to start Phase III trials by the end of July. On July 22, the Trump administration awarded a $1.9 billion contract for 100 million doses to be delivered by December and the option to acquire 500 million more doses. If approved, Pfizer said they expect to manufacture over 1.3 billion doses of their vaccine by the end of 2021.